Abstract.
The present study sought to evaluate the time-course of the effects of a short-acting glycine site NMDA receptor antagonist, MRZ 2/576 (half-life of about 20 min), on the expression of morphine withdrawal syndrome in mice. Morphine-naive and morphine-dependent mice (10–100 mg/kg, b.i.d., s.c., 9 days) were injected with a combination of naltrexone (vehicle or 1 mg/kg, s.c.) and MRZ 2/576 (vehicle, 0.3–10 mg/kg, i.p.) 24 h after the last morphine injection. MRZ 2/576 suppressed expression of several signs of morphine withdrawal (jumping, shaking, forelimb tremor). Effects of MRZ 2/576 were equally expressed throughout 1-h observation test of both spontaneous and naltrexone-facilitated withdrawal. These results suggest that despite its short half-life, MRZ 2/576 produces prolonged suppression of morphine withdrawal syndrome and this effect cannot be attributed to repeated morphine-induced increase in sensitivity to naltrexone.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Belozertseva, I., Danysz, W. & Bespalov, A. Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg's Arch Pharmacol 361, 279–282 (2000). https://doi.org/10.1007/s002109900179
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002109900179